Liquidia (NASDAQ:LQDA) General Counsel Sells $1,021,427.27 in Stock

Liquidia Corporation (NASDAQ:LQDA) General Counsel Russell Schundler sold 27,289 shares of Liquidia stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,021,427.27. Following the completion of the sale, the general counsel owned 579,394 shares in the company, valued at $21,686,717.42. This represents a 4.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Russell Schundler also recently made the following trade(s):

• On Monday, December 1st, Russell Schundler sold 1,072 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total value of $34,507.68.

Liquidia Stock Down 3.0%

Shares of LQDA opened at $38.79 on Friday. The company’s 50-day moving average price is $32.68 and its 200 day moving average price is $25.77. Liquidia Corporation has a 12-month low of $11.26 and a 12-month high of $41.57. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. The firm has a market cap of $3.37 billion, a P/E ratio of -26.94, a price-to-earnings-growth ratio of 0.68 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The business had revenue of $54.34 million during the quarter, compared to analysts’ expectations of $18.86 million. The firm’s revenue was up 1106.7% compared to the same quarter last year. On average, sell-side analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Wells Fargo & Company began coverage on Liquidia in a research report on Monday, October 20th. They set an “overweight” rating and a $31.00 price objective on the stock. BTIG Research reiterated a “buy” rating and issued a $49.00 target price on shares of Liquidia in a report on Friday, January 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Wednesday, October 8th. Finally, Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Liquidia currently has a consensus rating of “Moderate Buy” and an average price target of $39.67.

Institutional Trading of Liquidia

Institutional investors have recently bought and sold shares of the business. XTX Topco Ltd purchased a new stake in shares of Liquidia during the 2nd quarter worth approximately $1,485,000. Tyro Capital Management LLC acquired a new stake in Liquidia during the 2nd quarter worth $15,473,000. Diametric Capital LP lifted its position in Liquidia by 72.5% in the second quarter. Diametric Capital LP now owns 148,601 shares of the company’s stock valued at $1,852,000 after acquiring an additional 62,443 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Liquidia in the second quarter valued at $775,000. Finally, Pale Fire Capital SE acquired a new position in Liquidia in the second quarter valued at $1,068,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).